ERBB2 and cancer: Luminal B HER2 cancers displayed a significant reduction in LRR (16 vs. 1.8%, p < 0.001); however, there was no significant reduction in HER2+(ER−) breast cancers (16.7 vs. 10.6%, p = 0.261).